Exhibit 99.1


Sangamo BioSciences Announces Research and License Agreement With Genentech for
              ZFP Technology for Protein Pharmaceutical Production

      RICHMOND, Calif., April 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences,
Inc. (Nasdaq: SGMO) today announced that it had entered into a Research and
License Agreement with Genentech, Inc. Under this agreement, Sangamo will
provide Genentech with access to Sangamo's proprietary zinc finger DNA-binding
protein (ZFP) technology and will design and engineer ZFP nucleases (ZFN(TM))
for Genentech to evaluate and potentially use to generate cell lines with novel
characteristics for protein pharmaceutical production purposes. Financial terms
of the agreement were not disclosed.

      "We are very pleased to be able to provide Genentech, a leader in the
discovery, development, commercialization and manufacturing of biotherapeutics,
with a non-exclusive, research and commercial license to certain aspects of our
ZFP technology," said Edward Lanphier, Sangamo's president and chief executive
officer. "We have engineered ZFNs to facilitate the efficient generation of
production cell lines with altered traits. Our technology has the potential to
change the speed and efficiency of cell engineering to meet the increased demand
for proteins in a variety of industries including pharmaceutical protein
manufacturing."

      ZFPs are the dominant class of naturally occurring transcription factors
in organisms from yeast to humans. Transcription factors, which are found in the
nucleus of every cell, bind to DNA to regulate gene expression. Though there are
many kinds of transcription factors, only ZFPs are amenable to engineering and
precise targeting to a particular gene or genes of interest. ZFNs are engineered
forms of ZFPs that also contain a nuclease component, which can induce
modification of a target gene of interest.

      About Sangamo BioSciences, Inc.

      Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification. The
most advanced ZFP Therapeutic(TM) development program is currently in Phase 2
clinical trials for evaluation of safety and clinical effect in patients with
diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP
Therapeutic for peripheral artery disease. Other therapeutic development
programs are focused on HIV/AIDS, neuropathic pain, cancer, nerve regeneration,
ischemic heart disease and monogenic diseases. Sangamo's core competencies
enable the engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA
sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can
control gene expression and, consequently, cell function. Sangamo is also
developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene
modification as a treatment for a variety of monogenic diseases, such as
X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo
has established several Enabling Technology Agreements with companies to apply
its ZFP Technology to enhance the production of protein pharmaceuticals.
Research at Sangamo is partially funded by an Advanced Technology Program (ATP)
grant awarded by the National Institute of Standards and Technology (NIST). For
more information about Sangamo, visit the company's web site at
http://www.sangamo.com/ .

      This press release may contain forward-looking statements based on
Sangamo's current expectations. These forward-looking statements include,
without limitation, references to the research and development of novel ZFP TFs
and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP
technology platform. Actual results may differ materially from these
forward-looking statements due to a number of factors, including technological
challenges, Sangamo's ability to develop commercially viable products and
technological developments by our competitors. See the company's SEC filings,
and in particular, the risk factors described in the company's Annual Report on
Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the
forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.
04/30/2007

CONTACT: Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., +1-510-970-6000,
ext. 271, or ewolffe@sangamo.com; or Justin Jackson (media) of Burns McClellan,
Inc., +1-212-213-0006/ /Web site: http://www.sangamo.com/ (SGMO)